The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...
The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...
On Jan. 11, the Centers for Medicare and Medicaid Services announced a proposal to cover Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of ...
For decades, dementia, especially Alzheimer’s disease, was treated as untouchable. Families watched loved ones fade, doctors could offer only reassurance and coping strategies, and research seemed to ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results